• Home
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Our Approach
    • The B Cell Advantage
    • Research
  • Pipeline
  • News
    • Press Releases
    • News Articles
  • Careers
  • Contact
  • Home
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Our Approach
    • The B Cell Advantage
    • Research
  • Pipeline
  • News
    • Press Releases
    • News Articles
  • Careers
  • Contact

  • All
  • Press Releases
  • News Articles
    • Press Releases
    June 23, 2021

    Immusoft Announces Formation of Scientific Advisory Board

    Read More

    Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs.

    • Press Releases
    May 12, 2020

    Immusoft to Present at ASGCT 23rd Annual Meeting

    Read More

    – Two presentations to highlight the transposon-engineered B lymphocytes ISP™ platform for MPS I and enhancement of muscle mass – Seattle, Wash.–(BUSINESS WIRE) –May 12, 2020– Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced two upcoming virtual oral presentations at the ASGCT 23rd Annual…

    • Press Releases
    February 05, 2020

    Immusoft to Present at WORLDSymposium™ 2020

    Read More

    – Dr. McIvor, Chief Development Officer, to present on the Sleeping Beauty-Engineered B Lymphocytes ISP™ platform – Seattle, Wash.–(BUSINESS WIRE) –February 5, 2020– Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced that Scott McIvor, Ph.D., Chief Development Officer, and Professor Genetics, Cell Biology, and…

    • Press Releases
    September 10, 2019

    Immusoft to Present at the International Conference on Lymphocyte Engineering 2019

    Read More

    Dr. McIvor, Chief Development Officer, to present on the Sleeping Beauty-Engineered B Lymphocytes ISP™ platform

    • Press Releases
    July 17, 2019

    Immusoft Announces the Appointment of Robert Hayes, Ph.D. as Chief Scientific Officer

    Experienced leader in biotech platform development, Dr. Hayes to head research and advancement of ISP™ platform

    Read More

    Seattle, Wash.–(BUSINESS WIRE) –July17,2019–Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced the appointment of Robert Hayes, Ph.D., as Chief Scientific Officer. With nearly two decades of biologics discovery and development experience, Dr. Hayes will lead Immusoft’s preclinical research and spearhead the near-term advancement…

    • Press Releases
    January 03, 2019

    Immusoft Raises $20 Million in Series B Financing

    Robust financing to support advancement of Immusoft’s novel B cell platform

    Read More

    Seattle, Wash.–(BUSINESS WIRE) –January 3, 2019– Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today it has held the final closing in its $20 million oversubscribed Series B financing. Immusoft plans to use the proceeds from this financing to advance ISP-001 (iduronicrin genleukocel-T) through Phase I/II…

    • Press Releases
    October 17, 2018

    Immusoft Receives Rare Pediatric Disease Designation for Treatment of MPS I

    Read More

    SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted it Rare Pediatric Disease Designation (RPDD) for Iduronicrin genleukocel-T, Immusoft’s Sleeping Beauty transposon-engineered autologous plasmablasts for the expression and delivery of alpha-L-iduronidase (IDUA) to treat Mucopolysaccharidosis type I (MPS I).

    • Press Releases
    September 05, 2018

    Immusoft Receives $3.5 Million Grant to Expand upon Its Cell Therapy Platform

    Read More

    SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle, Wash.-based cell therapy company, announced today that it has received a Phase II Small Business Innovation Research grant (SBIR) from the National Institute of General Medical Sciences, part of the National Institutes of Health (NIH). The grant, in the amount of just over $3.5 million, will enable Immusoft to further advance its modified B cell approach to treating disease.

    • Press Releases
    May 02, 2018

    Immusoft Granted Orphan Drug Designation for Treatment of Rare Childhood Disease

    Read More

    SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle, Wash.-based gene therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to treat the first indication in the company’s pipeline, MPS I (Mucopolysaccharidosis type I).

    • Press Releases
    January 29, 2018

    Immusoft Recognized with “Most Promising Company Award” at Silicon Valley Conference

    Read More

    SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle, Wash.-based gene therapy company, announced today it is a winner of the Most Promising Company Award from the Precision Medicine World Conference, held in Silicon Valley last week. The award recognizes companies with especially promising and innovative health care diagnostic, therapeutic and technological solutions.

  • Older posts
    Newer posts
  • Home
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Our Approach
    • The B Cell Advantage
    • Research
  • Pipeline
  • News
    • Press Releases
    • News Articles
  • Careers
  • Contact

© IMMUSOFT 2023 | 454 N 34th St., Seattle, WA 98103 | Directions | info@immusoft.com